Coherus Oncology (CHRS) Debt to Equity: 2014-2025
Historic Debt to Equity for Coherus Oncology (CHRS) over the last 10 years, with Sep 2025 value amounting to $0.42.
- Coherus Oncology's Debt to Equity rose 180.84% to $0.42 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.42, marking a year-over-year increase of 180.84%. This contributed to the annual value of -$0.38 for FY2024, which is 70.48% up from last year.
- According to the latest figures from Q3 2025, Coherus Oncology's Debt to Equity is $0.42, which was up 36.85% from $0.31 recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Debt to Equity registered a high of $15.59 during Q1 2022, and its lowest value of -$8.66 during Q2 2022.
- Moreover, its 3-year median value for Debt to Equity was -$0.54 (2024), whereas its average is -$0.71.
- Data for Coherus Oncology's Debt to Equity shows a peak YoY increase of 2,564.54% (in 2022) and a maximum YoY decrease of 1,905.47% (in 2022) over the last 5 years.
- Quarterly analysis of 5 years shows Coherus Oncology's Debt to Equity stood at $0.77 in 2021, then slumped by 331.19% to -$1.79 in 2022, then increased by 27.71% to -$1.29 in 2023, then spiked by 70.48% to -$0.38 in 2024, then surged by 180.84% to $0.42 in 2025.
- Its Debt to Equity was $0.42 in Q3 2025, compared to $0.31 in Q2 2025 and -$0.34 in Q1 2025.